Special Issue "Endocrinology in the Time of COVID-19"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 10 June 2022.

Special Issue Editors

Dr. Anca Pantea Stoian
E-Mail Website
Guest Editor
Diabetes, Nutrition and Metabolic Diseases Department, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Str., 050474 Bucharest, Romania
Interests: diabetes; nutrition; metabolic diseases; chronic kidney disease
Special Issues, Collections and Topics in MDPI journals
Dr. Nader Lessan
E-Mail Website
Guest Editor
Imperial College London, London, UK
Interests: diabetes mellitus; hypertension; dietetics; nutritional medicine; diabetes complications; diabetes

Special Issue Information

Dear Colleagues, 

COVID-19 has introduced rapidly evolving aspects to our understanding and management of the whole spectrum of available medical information. Among the medical subspecialties that have been affected uniquely by COVID-19 is the discipline of endocrinology. Indeed, the pandemic has affected multifaceted aspects of endocrine care and, for instance, subjects with diabetes or obesity with SARS CoV-2 infection have been shown worldwide to develop more severe forms of COVID that may require life-sustaining care and hospitalization. In addition, both lifestyle and nutrition during the pandemic were significantly affected, increasing the vulnerability of patients with endocrine disorders.

A considerable jump of a logarithmic scale in the COVID era has been the galactic advances in health care technology, covering telehealth delivery of health care, from initiation in the inpatient setting and transitioning to discharge and outpatient use. It is critically important that a timely and updated compendium be put together of the vast amounts of knowledge and data related to endocrinology that has been gained since the beginning of the COVID-19 pandemic. Given the urgency and complexity of this topic and its impact on both clinical practice and public health, we now launch in Medicina a Special Issue entitled “Endocrinology in the Time of COVID-19”, with the aim of gathering together a scientific repository on the association between COVID-19 and endocrine dysfunction.

We are delighted to invite you to submit your original research articles and manuscripts covering basic and clinical research focusing on COVID-19, hormonal perturbations, glucometabolic health, and vaccination for those with endocrine and metabolic diseases. Concise and valuable review articles aimed at providing a comprehensive understanding of how the SARS CoV-2 virus has impacted the science of endocrinology are also welcome. We hope that you will also consider adding your experience to the therapeutic armamentarium that exists to combat this modern-day challenge to human health.

Dr. Manfredi Rizzo
Dr. Anca Pantea Stoian
Dr. Ali Abbas Rizvi
Dr. Nader Lessan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • SARS CoV virus
  • endocrine dysfunction
  • hyperglycemia
  • diabetes
  • obesity
  • inflammation
  • hormones
  • nutrition
  • lifestyle
  • vaccination

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Other

Editorial
Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care
Medicina 2021, 57(8), 805; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57080805 - 06 Aug 2021
Cited by 2 | Viewed by 515
Abstract
American singer-writer and visual artist Bob Dylan produced the song “The Times They Are a-Changin” in the 1960s, which became a rallying cry for the civil rights and anti-war movements in that decade [...] Full article
(This article belongs to the Special Issue Endocrinology in the Time of COVID-19)

Other

Jump to: Editorial

Commentary
Inherited/Genetically-Associated Pheochromocytoma/ Paraganglioma Syndromes and COVID-19
Medicina 2021, 57(10), 1033; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57101033 - 28 Sep 2021
Viewed by 330
Abstract
In some subjects with inherited pheochromocytoma/paraganglioma (PPG) syndromes, hypoxia-inducible factor 1 alpha (HIF1α) stabilization/activation could lead to an increase in angiotensin converting enzymes (ACE). This would result in the stimulation of angiotensin (AT) II production and, hence, reduce the availability of ACE 2. [...] Read more.
In some subjects with inherited pheochromocytoma/paraganglioma (PPG) syndromes, hypoxia-inducible factor 1 alpha (HIF1α) stabilization/activation could lead to an increase in angiotensin converting enzymes (ACE). This would result in the stimulation of angiotensin (AT) II production and, hence, reduce the availability of ACE 2. The latter would provide decreased numbers of binding sites for the spike protein of SARS-CoV-2 and, therefore, result in less points of viral entry into cells. Thus, subjects with HIF1α-associated PPG syndromes may benefit from an inherent protective effect against COVID-19. Such an implication of HIF1α vis-à-vis COVID-19 could open ways of therapeutic interventions. Full article
(This article belongs to the Special Issue Endocrinology in the Time of COVID-19)
Back to TopTop